^
CANCER:

Adenoid Cystic Carcinoma

MYB underexpression
Adenoid Cystic Carcinoma
tretinoin
Sensitive: C3 – Early Trials
NOTCH1 mutation
Adenoid Cystic Carcinoma
tretinoin
Sensitive: C3 – Early Trials
NOTCH mutation
Adenoid Cystic Carcinoma
AL101
Sensitive: C3 – Early Trials
NOTCH1 positive + FGFR2 mutation
Adenoid Cystic Carcinoma
lenvatinib + erdafitinib + γ-secretase inhibitor
Sensitive: C4 – Case Studies
MYB-NFIB fusion + BCOR F1106Tfs*5 + BCOR L1524Hfs*8
Adenoid Cystic Carcinoma
anlotinib + eribulin mesylate
Sensitive: C4 – Case Studies
BCOR L1524Hfs*8
Adenoid Cystic Carcinoma
anlotinib
Sensitive: C4 – Case Studies
BCOR F1106Tfs*5
Adenoid Cystic Carcinoma
anlotinib
Sensitive: C4 – Case Studies
MYB-NFIB fusion
Adenoid Cystic Carcinoma
M6620
Sensitive: D – Preclinical
PIK3CA mutation
Adenoid Cystic Carcinoma
PI3K inhibitor
Sensitive: D – Preclinical
MYB fusion + PIK3CA mutation
Adenoid Cystic Carcinoma
PI3K inhibitor
Sensitive: D – Preclinical